Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/305% above fair value
$68.29−0.21 (-0.31%)
Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –
Exelixis operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Exelixis's operating cash flow for the twelve months ending Oct 2, 2026 was $1.17B, up 48.3% year over year. For fiscal 2025 it was $884.27M, up 26.3% from the year before. The highest annual figure on record is $884.27M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $884.27M | +26.3% |
| FY2024 | Jan 3, 2025 | $699.97M | +110.0% |
| FY2023 | Dec 29, 2023 | $333.32M | -8.1% |
| FY2022 | Dec 30, 2022 | $362.61M | -9.5% |
| FY2021 | Dec 31, 2021 | $400.80M | +91.8% |
| FY2020 | Jan 1, 2021 | $208.98M | -60.3% |
| FY2019 | Jan 3, 2020 | $526.96M | +26.8% |
| FY2018 | Dec 28, 2018 | $415.72M | +151.0% |
| FY2017 | Dec 29, 2017 | $165.61M | -21.3% |
| FY2016 | Dec 31, 2016 | $210.40M | – |
| FY2015 | Dec 31, 2015 | -$141.05M | – |
| FY2014 | Dec 31, 2014 | -$235.41M | – |
| FY2013 | Dec 31, 2013 | -$198.77M | – |
| FY2012 | Dec 31, 2012 | -$123.15M | – |
| FY2011 | Dec 31, 2011 | -$159.23M | – |
| FY2010 | Dec 31, 2010 | -$101.05M | – |
| FY2009 | Dec 31, 2009 | -$14.59M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $279.96M | -3.6% |
| Q2 FY2026 | Jul 3, 2026 | $307.74M | +528.1% |
| Q1 FY2026 | Apr 3, 2026 | $251.85M | +19.1% |
| Q4 FY2025 | Jan 2, 2026 | $333.52M | +38.8% |
| Q3 FY2025 | Oct 3, 2025 | $290.32M | +7.0% |
| Q2 FY2025 | Jul 4, 2025 | $48.99M | -59.0% |
| Q1 FY2025 | Apr 4, 2025 | $211.44M | +207.2% |
| Q4 FY2024 | Jan 3, 2025 | $240.26M | +2172.9% |
| Q3 FY2024 | Sep 27, 2024 | $271.34M | +131.2% |
| Q2 FY2024 | Jun 28, 2024 | $119.55M | -1.2% |
| Q1 FY2024 | Mar 29, 2024 | $68.82M | -18.5% |
| Q4 FY2023 | Dec 29, 2023 | $10.57M | -85.7% |
| Q3 FY2023 | Sep 29, 2023 | $117.37M | +6.6% |
| Q2 FY2023 | Jun 30, 2023 | $120.98M | +288.6% |
| Q1 FY2023 | Mar 31, 2023 | $84.41M | -42.9% |
| Q4 FY2022 | Dec 30, 2022 | $73.69M | -23.6% |
| Q3 FY2022 | Sep 30, 2022 | $110.07M | +32.1% |
| Q2 FY2022 | Jul 1, 2022 | $31.13M | -82.8% |
| Q1 FY2022 | Apr 1, 2022 | $147.72M | +273.6% |
| Q4 FY2021 | Dec 31, 2021 | $96.45M | +189.7% |
| Q3 FY2021 | Oct 1, 2021 | $83.31M | +364.4% |
| Q2 FY2021 | Jul 2, 2021 | $181.50M | +78.5% |
| Q1 FY2021 | Apr 2, 2021 | $39.54M | -29.5% |
| Q4 FY2020 | Jan 1, 2021 | $33.29M | -78.9% |
| Q3 FY2020 | Oct 2, 2020 | $17.94M | -76.3% |
| Q2 FY2020 | Jul 3, 2020 | $101.68M | -22.8% |
| Q1 FY2020 | Apr 3, 2020 | $56.07M | -65.3% |
| Q4 FY2019 | Jan 3, 2020 | $158.02M | +51.1% |
| Q3 FY2019 | Sep 27, 2019 | $75.61M | -54.1% |
| Q2 FY2019 | Jun 28, 2019 | $131.73M | +76.9% |
| Q1 FY2019 | Mar 29, 2019 | $161.59M | +125.0% |
| Q4 FY2018 | Dec 28, 2018 | $104.59M | +96.0% |
| Q3 FY2018 | Sep 28, 2018 | $164.86M | +335.4% |
| Q2 FY2018 | Jun 29, 2018 | $74.47M | +1245.3% |
| Q1 FY2018 | Mar 30, 2018 | $71.81M | +4.3% |
| Q4 FY2017 | Dec 29, 2017 | $53.35M | -37.3% |
| Q3 FY2017 | Sep 30, 2017 | $37.87M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.54M | – |
| Q1 FY2017 | Mar 31, 2017 | $68.86M | – |
| Q4 FY2016 | Dec 31, 2016 | $85.11M | – |
See a number that looks wrong?